2012-10-10 01:10:19 - Fast Market Research recommends "Axxam SpA - Product Pipeline Review - 2012" from Global Markets Direct, now available

Global Market Direct's pharmaceuticals report, "Axxam SpA - Product Pipeline Review - 2012" provides data on the Axxam SpA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Axxam SpA's corporate website, SEC filings, investor presentations and featured press releases, both from Axxam SpA and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468510_axxam_spa_product_pipeline_review_201 ..


Scope

* Axxam SpA - Brief Axxam SpA overview including business description, key information and facts, and its locations and subsidiaries.
*

Review of current pipeline of Axxam SpA human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Axxam SpA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Axxam SpA's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Reasons to buy

* Evaluate Axxam SpA's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Axxam SpA in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Axxam SpA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Axxam SpA.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Axxam SpA and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Axxam SpA Snapshot
Axxam SpA Overview
Key Information
Key Facts
Axxam SpA - Research and Development Overview
Key Therapeutic Areas
Axxam SpA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Axxam SpA - Pipeline Products Glance
Axxam SpA - Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Axxam SpA - Drug Profiles
Bradykinin R1 Antagonist
Product Description
Mechanism of Action
R&D Progress
CB-2R Agonist
Product Description
Mechanism of Action
R&D Progress
GPR-120 Agonist
Product Description
Mechanism of Action
R&D Progress
Kv1.3 Blocker
Product Description
Mechanism of Action
R&D Progress
Nav1.7 Blocker
Product Description
Mechanism of Action
R&D Progress
P2X7 Blocker
Product Description
Mechanism of Action
R&D Progress
TRPM8 Blocker
Product Description
Mechanism of Action
R&D Progress
Axxam SpA - Pipeline Analysis
Axxam SpA - Pipeline Products by Therapeutic Class
Axxam SpA - Pipeline Products By Mechanism of Action
Axxam SpA - Dormant Projects
Axxam SpA - Locations And Subsidiaries
Head Office
Financial Deals Landscape
Axxam SpA, Deals Summary
Axxam SpA, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Axxam Acquires Molecular Screening Technologies From Bayer HealthCare
Partnerships
Fast Forward And Juvenile Diabetes Research Foundation Extend Co-Development Agreement With Axxam
Axxam Enters Into Co-Development Agreement With Polyphor
Axxam Forms Joint Venture With InterMed Discovery
Polyphor Enters Into Co-Development Agreement With Axxam
Fast Forward And Juvenile Diabetes Research Enter Into Co-Development Agreement With Axxam
Xenome Enters Into Research Collaboration Agreement With Axxam
Dompe Farmaceutici Extends Drug Discovery Collaboration With Axxam
InterMed Enters Into Co Development Agreement With Axxam
Genedata Enters Into Collaboration Agreement With Axxam
Axxam Enters Into Drug Discovery Collaboration With Boehringer Ingelheim
Axxam Enters Into Drug Discovery Agreement With Dompe Framaceutici
Licensing Agreements
Axxam Enters Into Licensing Agreement With Lonza Group
Axxam Enters Into Licensing Agreement With PerkinElmer
Axxam Enters Into Licensing Agreement With National Institutes of Health
Asset Transactions
Boehringer Ingelheim Acquires Protein Material And Specific Functional Assay From Axxam
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Axxam SpA, Key Information
Axxam SpA, Key Facts
Axxam SpA - Pipeline by Indication, 2012
Axxam SpA - Pipeline by Stage of Development, 2012
Axxam SpA - Monotherapy Products in Pipeline, 2012
Axxam SpA - Discovery, 2012
Axxam SpA - Pipeline By Therapeutic Class, 2012
Axxam SpA - Pipeline Products By Mechanism of Action, 2012
Axxam SpA - Dormant Developmental Projects,2012
Axxam SpA, Deals Summary
Axxam Acquires Molecular Screening Technologies From Bayer HealthCare

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468510&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.